Cempra planning follow-on

Cempra Inc. (NASDAQ:CEMP) proposed a follow-on late Thursday underwritten by Barclays; Stifel; and Cowen. Cempra also said it will start in 4Q13 a Phase III trial of lead product solithromycin to treat community-acquired bacterial pneumonia (CABP). The trial will compare IV solithromycin with IV moxifloxacin in about 800 patients who will then be switched to oral formulations of the antibiotics. The oral formulation of solithromycin is already in a Phase III trial for CABP. Cempra, which made both announcements after market close, was up $0.18 to $8.13 on Thursday. ...